A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase
1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics
(PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell
malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a
monotherapy and in combination with chemotherapy for evaluation in these patients.